|
|
Blood, 15 July 2006, Vol. 108, No. 2, pp. 705-710.
Prepublished online as a Blood First Edition Paper on March 21, 2006; DOI 10.1182/blood-2005-11-4607.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors
Meili Zhang,
Zhengsheng Yao,
Zhuo Zhang,
Kayhan Garmestani,
Carolyn K. Goldman,
Jeffrey V. Ravetch,
John Janik,
Martin W. Brechbiel, and
Thomas A. Waldmann
From the Metabolism Branch, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and the Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY.
CD30 is a member of the tumor necrosis factor receptor family. Overexpression of CD30 on some neoplasms versus its limited expression on normal tissues makes this receptor a promising target for antibody-based therapy. Anaplastic large-cell lymphoma (ALCL) represents a heterogeneous group of aggressive non-Hodgkin lymphomas characterized by the strong expression of CD30. We investigated the therapeutic efficacy of HeFi-1, a mouse IgG1 monoclonal antibody, which recognizes the ligand-binding site on CD30, and humanized anti-Tac antibody (daclizumab), which recognizes CD25, in a murine model of human ALCL. The ALCL model was established by intravenous injection of karpas299 cells into nonobese diabetic/severe combined immuno-deficient (SCID/NOD) wild-type or SCID/NOD Fc receptor common  chain–deficient (FcR–/–) mice. HeFi-1, given at a dose of 100 µg weekly for 4 weeks, significantly prolonged survival of the ALCL-bearing SCID/NOD wild-type and SCID/NOD FcR–/– mice (P < .01) as compared with the control groups. In vitro studies showed that HeFi-1 inhibited the proliferation of karpas299 cells, whereas daclizumab did not inhibit cell proliferation. We demonstrated that the expression of FcR on polymorphonuclear leukocytes and monocytes was not required for HeFi-1–mediated tumor growth inhibition in vivo, although it was required for daclizumab.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. M. Cardarelli, M.-C. Moldovan-Loomis, B. Preston, A. Black, D. Passmore, T.-H. Chen, S. Chen, J. Liu, M. R. Kuhne, M. Srinivasan, et al.
In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant Lymphoma
Clin. Cancer Res.,
May 15, 2009;
15(10):
3376 - 3383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Font-Llitjos, L. Feliubadalo, M. Espino, R. Cleries, S. Manas, I. M. Frey, S. Puertas, G. Colell, S. Palomo, J. Aranda, et al.
Slc7a9 knockout mouse is a good cystinuria model for antilithiasic pharmacological studies
Am J Physiol Renal Physiol,
September 1, 2007;
293(3):
F732 - F740.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Damm-Welk, K. Busch, B. Burkhardt, J. Schieferstein, S. Viehmann, I. Oschlies, W. Klapper, M. Zimmermann, J. Harbott, A. Reiter, et al.
Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma
Blood,
July 15, 2007;
110(2):
670 - 677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Yao, H. Patel, K. Garmestani, Z. Zhang, V. S. Talanov, P. S. Plascjak, C. K. Goldman, J. E. Janik, M. W. Brechbiel, et al.
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1
PNAS,
May 15, 2007;
104(20):
8444 - 8448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, S. Yu, H.-S. Kim, C. K. Goldman, C. H. Paik, et al.
The Anti-CD25 Monoclonal Antibody 7G7/B6, Armed with the {alpha}-Emitter 211At, Provides Effective Radioimmunotherapy for a Murine Model of Leukemia
Cancer Res.,
August 15, 2006;
66(16):
8227 - 8232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
